awmsg logo



darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®)


Reference No. 2418


Appraisal information

darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) 800 mg/150 mg/200 mg/10 mg film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download